ABIONYX Pharma S.A.
ABNX.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €4,600 | €4,640 | €5,252 | €675 |
| % Growth | -0.9% | -11.7% | 678.1% | – |
| Cost of Goods Sold | €3,700 | €4,022 | €4,616 | €416 |
| Gross Profit | €844 | €618 | €636 | €259 |
| % Margin | 18.3% | 13.3% | 12.1% | 38.4% |
| R&D Expenses | €2,986 | €2,902 | €2,563 | €5,677 |
| G&A Expenses | €1,286 | €1,106 | €1,188 | €503 |
| SG&A Expenses | €1,286 | €1,106 | €1,188 | €503 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | €1,037 | €22 | €994 | €31 |
| Operating Expenses | €5,309 | €4,030 | €4,745 | €6,211 |
| Operating Income | -€5,572 | -€3,412 | -€4,109 | -€5,952 |
| % Margin | -121.1% | -73.5% | -78.2% | -881.8% |
| Other Income/Exp. Net | €84 | -€106 | -€97 | €130 |
| Pre-Tax Income | -€5,467 | -€3,518 | -€4,206 | -€5,822 |
| Tax Expense | -€1,067 | €0 | -€1,456 | €8 |
| Net Income | -€4,400 | -€3,518 | -€4,206 | -€5,822 |
| % Margin | -95.7% | -75.8% | -80.1% | -862.5% |
| EPS | -0.13 | -0.12 | -0.15 | -0.23 |
| % Growth | -8.3% | 20% | 34.8% | – |
| EPS Diluted | -0.13 | -0.12 | -0.15 | -0.23 |
| Weighted Avg Shares Out | 33,695 | 29,350 | 27,967 | 24,880 |
| Weighted Avg Shares Out Dil | 33,695 | 29,350 | 27,967 | 24,880 |
| Supplemental Information | – | – | – | – |
| Interest Income | €104 | €60 | €6 | €4 |
| Interest Expense | €61 | €19 | €240 | €124 |
| Depreciation & Amortization | €478 | -€160 | €135 | €119 |
| EBITDA | -€4,928 | -€4,844 | -€4,010 | -€7,418 |
| % Margin | -107.1% | -104.4% | -76.4% | -1,099% |